Literature DB >> 8869090

Sex as a prognostic factor in gastric cancer.

A Maguire1, M Porta, J M Sanz-Anquela, I Ruano, N Malats, J L Piñol.   

Abstract

The aim of this study was to assess whether survival of gastric cancer patients differed between males and females. Although it is well known that the incidence of gastric cancer is higher for men than for women, the existence of a sex-specific prognosis has seldom been addressed. Studies based on population registries have not assessed the role of stage and histology. Cases of histologically confirmed gastric carcinoma were obtained from three Spanish hospitals in Soria (n = 405), Barcelona (n = 249) and Mataró (n = 197). Differences in possible confounders were tested between men and women and survival analyses were performed separately by hospital. Cox's proportional hazards models were used to account for age, tumour stage, histology and tumour sub-location. Only in Mataró was a significant difference in the stage distribution observed between women and men, with a lower proportion of local stage tumours among women (P = 0.047). No statistically significant differences of histological type between men and women were observed in any of the centres. After adjusting for tumour stage and age, women were observed to have significantly better survival in Barcelona (female to male hazard ratio (HR) = 0.578, P < 0.001); this effect was marginal in Soria (HR = 0.788, P = 0.092) and non-significant in Matar-o (HR = 0.895, P = 0.54). Age-adjusted hazard ratios were calculated within each tumour stage. For Barcelona, the effect of better prognosis among women was most marked at local stage (HR = 0.320, P = 0.013), and in Soria at the regional stage (HR = 0.426, P = 0.002). Although in Mataró all HRs were below unity, none were statistically significant. Little effect was observed at the disseminated stage. The other covariables exerted no influence. Women appear to have a better prognosis than men, and the difference could be tumour stage dependent. Confirmation of these findings would give a valuable insight into gastric cancer growth and ultimately be of use in planning treatment.

Entities:  

Mesh:

Year:  1996        PMID: 8869090     DOI: 10.1016/0959-8049(96)00103-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: comparative analysis of subgroups in stage II.

Authors:  Joong-Min Park; Jong-Han Kim; Sung-Soo Park; Seung-Joo Kim; Young-Jae Mok; Chong-Suk Kim
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

2.  Clinicopathological features of female gastric carcinoma patients with curative resection: comparison with male patients.

Authors:  Ho Goon Kim; Hoi Dong Ghu; Sang Kwon Yun; Seong Yeob Ryu; Dong Yi Kim
Journal:  Chonnam Med J       Date:  2012-08-24

3.  Gender and ploidy in cancer survival.

Authors:  Susanne Schulze; Iver Petersen
Journal:  Cell Oncol (Dordr)       Date:  2011-03-22       Impact factor: 6.730

4.  Simultaneous Quantification of Serum Multi-Phospholipids as Potential Biomarkers for Differentiating Different Pathophysiological states of lung, stomach, intestine, and pancreas.

Authors:  Yumei Guo; Junling Ren; Xiaoou Li; Xiaofeng Liu; Ning Liu; Yanmin Wang; Zhili Li
Journal:  J Cancer       Date:  2017-07-15       Impact factor: 4.207

5.  Do Sex-Related Differences of Comorbidity Burden and/or In-Hospital Mortality Exist in Cancer Patients? A Retrospective Study in an Internal Medicine Setting.

Authors:  Alfredo De Giorgi; Fabio Fabbian; Rosaria Cappadona; Ruana Tiseo; Christian Molino; Elisa Misurati; Edoardo Gambuti; Caterina Savriè; Benedetta Boari; Valeria Raparelli; Roberto Manfredini
Journal:  Life (Basel)       Date:  2021-03-22

6.  Sex as a Prognostic Factor in Systematic Reviews: Challenges and Lessons Learned.

Authors:  Elena Stallings; Alba Antequera; Jesús López-Alcalde; Miguel García-Martín; Gerard Urrútia; Javier Zamora
Journal:  J Pers Med       Date:  2021-05-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.